Languages Available
 
C

PT. Kalbe Farma Tbk [KLBF]   IDR 1.290  +15 (1,18%)


Loading...
KLBF IDR 1.290  +15 (1,18%)
Last Update 18 July 2018 01:09 PM
Open
IDR 1.275
Prev Close
IDR 1.275
Offer
IDR 1.295
Bid
IDR 1.290
Day Low
IDR 1.275
Day High
IDR 1.305
Volume
35.224 Lots (3.522.400 Shares)
Transaction Value (IDR)
4.559,05 M
Frequency
552 (Times)
EPS (IDR)
50,30
PE Ratio (ttm)
25,65 Times
Market Cap. (IDR)
60.468.750,00 M
Market Cap. Rank in Industry
#1 of 11 Companies in Pharmaceuticals
Market Cap. Rank in All Companies
#18 of 617 Companies
F
Net Foreign

This section of IDNFinancials requires you to sign up as a premium member of IDNFinancials.

Please check our pricing page to see all of our features.
O
Overview


PT. Kalbe Farma Tbk (KLBF) is engaged in the development, manufacturing and trading of pharmaceutical preparation including medicines and consumer health products.The Company started its commercial operations in 1966.

Subsidiary Affiliation
 
Company Name
Percentage
1.
Innogene Kalbiotech Pte Ltd
93,34 %
2.
Kalbe Global Pte Ltd
100,00 %
3.
Kalbe International Pte Ltd
100,00 %
4.
Kalbe Vision Pte Ltd
100,00 %
5.
PT. Bifarma Adiluhung
100,00 %
6.
PT. Bintang Toedjoe
100,00 %
7.
PT. Dankos Farma
100,00 %
8.
PT. Enseval Putera Megatrading Tbk
91,80 %
9.
PT. Finusolprima Farma Internasional
100,00 %
10.
PT. Hale International
100,00 %
11.
PT. Hexpharm Jaya Laboratories
100,00 %
12.
PT. Kalbe Milko Indonesia
51,00 %
13.
PT. Kalbe Morinaga Indonesia
70,00 %
14.
PT. Kalbio Global Medika
100,00 %
15.
PT. Pharma Metric Labs
81,64 %
16.
PT. Saka Farma Laboratories
100,00 %
17.
PT. Sanghiang Perkasa
100,00 %
I
IPO
IPO Date30 July 1991
Offering Shares10.000.000
Company Listing10.000.000
Total List Shares20.000.000
Percentage50,00 %
Offering PriceRp 7.800
Fund RaisedRp 78.000.000.000
Securities Administration BureauPT. Adimitra Jasa Korpora
Lead UnderwriterPT. Merincorp, PT. Niaga Securities
Listing BoardMain
No IPO bonds found
No IPO rights issue found
D
Dividend

This section of IDNFinancials requires you to sign up as a premium member of IDNFinancials.

Please check our pricing page to see all of our features.
G
Management
Commissioners
-
President Commissioner
Commissioner
Commissioner
Commissioner
Independent Commissioner
Independent Commissioner
Independent Commissioner
Directors
-
President Director
Director
Director
Sie Djohan
Independent Director
Bernadus Karmin Winata
Graph goes here...
S
Shareholders
No. Shareholder Name Number of Shares Total Paidup Capital Percentage
1. Public (each below 5%) 20.261.045.725 IDR 202.610.457.250 43,23 %
2. PT. Gira Sole Prima 4.774.709.485 IDR 47.747.094.850 10,19 %
3. PT. Diptanala Bahana 4.454.807.040 IDR 44.548.070.400 9,50 %
4. PT. Ladang Ira Panen 4.356.854.940 IDR 43.568.549.400 9,29 %
5. PT. Lucasta Murni Cemerlang 4.439.895.440 IDR 44.398.954.400 9,47 %
6. PT. Santa Seha Sanadi 4.527.734.940 IDR 45.277.349.400 9,66 %
7. PT. Bina Arta Charisma 4.060.074.540 IDR 40.600.745.400 8,66 %
V
Videos
IDNFinancials Video - Lemahnya rupiah berdampak pada produsen farmasi, Kalbe tetap optimis pada target
05 August 2013 03:10 PM
Perusahaan farmasi PT Kalbe Farma Tbk (KLBF) mengakui pelemahan rupiah akhir-akhir ini masih negatif meski masih meyakini target penjualan tahun ini. Pemimpin industri farmasi Indonesia melihat dampak pada melemahnya mata uang mungkin terjadi tidak segera karena mereka memiliki persediaan dan uang tunai dolar AS yang seimbang...
A
Announcement
Kalbe Farma will hold annual shareholders meeting on June 5, 2018
2018-04-20 23:00:58
Links: [1] [2]
Kalbe Farma distributes cash dividend Rp 22 per Share Cum June 12, 2017
2017-06-07 14:53:02
Links: [1] [2]
Kalbe Farma will hold annual shareholders' meeting on June 5, 2017
2017-04-28 11:29:02
Links: [1] [2]
Kalbe Farma pays dividend Rp19 per share cum June 7, 2016
2016-06-02 23:30:06
Links: [1] [2]
Kalbe Farma will hold annual shareholders' meeting on May 31, 2016
2016-04-15 11:03:12
Links: [1] [2]
S
Financial
Period Revenue Net Profit
Q1 - 2018 5.014.905 M 589.439 M
Q4 - 2017 5.092.223 M 624.199 M
Q3 - 2017 5.023.593 M 563.148 M
Q2 - 2017 5.167.956 M 628.006 M
Q1 - 2017 4.898.348 M 588.252 M
Q4 - 2016 4.998.081 M 597.067 M
Q3 - 2016 4.820.356 M 556.454 M
Q2 - 2016 5.006.052 M 582.976 M
Full financial and operational data available to our premium users. Please check our premium data introduction page to learn more about our tools.
No prospectus found